GlobeNewsWire
21 Nov 2025, 14:30 UTC · 44w ago
Verdict
Headline leans bearish. We score ATRA −1.00 across two claims.
Score confirms the headline.
Leans bearish
From its wording — no explicit rating
−1.00strongly bearish
What the story claims
2 claims · scored −1 bearish … +1 bullish
DexCom made changes to its G6 and G7 continuous glucose monitoring systems without FDA authorization, leaving products less reliable and posing a health risk to users.
More negative than 99% of claims this week
A class action lawsuit has been filed against DexCom alleging the company downplayed the severity of health risks its products posed and made materially misleading statements between July 2024 and September 2025.
Continue reading
5 related stories
More negative than 95% of ticker scores this week
Scored by the NIS engine · methodology.
Top 1 mover · tap to explore
More negative than 95% of claims this week
Which stocks this story touches
More negative than 95% of ticker scores this week
The company is named as the target of a securities fraud lawsuit.
More negative than 95% of ticker scores this week
The company is facing a securities fraud class action lawsuit alleging false statements regarding product reliability and health risks.
More negative than 84% of ticker scores this week
The company is mentioned as being under a fraud investigation.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Newsfile Corp
19h ago
−35.7%
Price agrees with the score
$8.50 vs $13.22 close before publication (Nov 20) · not market-adjusted
ATRA chart →
